{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:47:29Z","timestamp":1791298049039,"version":"4.1.0"},"reference-count":365,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.pharmthera.2013.11.009","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T03:02:57Z","timestamp":1385434977000},"page":"99-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["p53 in neurodegenerative diseases and brain cancers"],"prefix":"10.1016","volume":"142","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Checler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristine","family":"Alves da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.11.009_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(03)01031-6","article-title":"Mammalian prion biology: one century of evolving concepts","volume":"116","author":"Aguzzi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1096\/fj.04-1621fje","article-title":"Protective effect of TAT-delivered a-synuclein: relevance of the C-terminal domain and involvement of HSP70","volume":"18","author":"Albani","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2009.10.004","article-title":"Targeting the ubiquitin\u2013proteasome system to activate wild-type p53 for cancer therapy","volume":"20","author":"Allende-Vega","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-6-36","article-title":"Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo","volume":"6","author":"Altmeppen","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1566524033361690","article-title":"Recent advances on a-synuclein cell biology: functions and dysfunctions","volume":"3","author":"Alves da Costa","year":"2003","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/156720505774932278","article-title":"Recent insights on the pro-apoptotic phenotype elicited by presenilin 2 and its caspase and presenilinase-derived fragments","volume":"2","author":"Alves da Costa","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0055","doi-asserted-by":"crossref","first-page":"12064","DOI":"10.1074\/jbc.M212379200","article-title":"The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart","volume":"278","author":"Alves da Costa","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0060","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1073\/pnas.062059899","article-title":"Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons","volume":"99","author":"Alves da Costa","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0065","doi-asserted-by":"crossref","first-page":"50980","DOI":"10.1074\/jbc.M207825200","article-title":"Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease","volume":"277","author":"Alves Da Costa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0070","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1523\/JNEUROSCI.0651-06.2006","article-title":"Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease","volume":"26","author":"Alves da Costa","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jnr.22186","article-title":"Interplay between 20S proteasomes and prion proteins in scrapie disease","volume":"88","author":"Amici","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0080","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.freeradbiomed.2008.08.028","article-title":"Opposing roles of prion protein in oxidative stress- and ER stress-induced apoptotic signaling","volume":"45","author":"Anantharam","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0197-4580(00)00126-3","article-title":"Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL","volume":"21","author":"Anderson","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0090","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1523\/JNEUROSCI.16-05-01710.1996","article-title":"DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay","volume":"16","author":"Anderson","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0095","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ncb1101-1030","article-title":"Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts","volume":"3","author":"Armogida","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molonc.2011.07.007","article-title":"p53: guardian of ploidy","volume":"5","author":"Aylon","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1471-4159.2001.00370.x","article-title":"C-terminal fragment of amyloid precursor protein induces astrocytosis","volume":"78","author":"Bach","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1471-4914(03)00020-0","article-title":"Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease","volume":"9","author":"Barzilai","year":"2003","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.parkreldis.2009.11.005","article-title":"Cancer risk in association with Parkinson disease: a population-based study","volume":"16","author":"Becker","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0125","doi-asserted-by":"crossref","first-page":"a000935","DOI":"10.1101\/cshperspect.a000935","article-title":"Transcriptional regulation by p53","volume":"2","author":"Beckerman","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0135","doi-asserted-by":"crossref","first-page":"41443","DOI":"10.1074\/jbc.M110.141390","article-title":"The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway","volume":"285","author":"Belyaev","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0140","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin\u2013proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0145","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11064-005-6877-5","article-title":"Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease","volume":"30","author":"Biswas","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0155","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1073\/pnas.93.16.8379","article-title":"Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90","volume":"93","author":"Blagosklonny","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/01.wnl.0000198511.09968.b3","article-title":"Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease","volume":"66","author":"Blandini","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","article-title":"Recent advances in the molecular understanding of glioblastoma","volume":"108","author":"Bleeker","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0170","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cub.2007.06.068","article-title":"p53-mediated activation of miRNA34 candidate tumor-suppressor genes","volume":"17","author":"Bommer","year":"2007","journal-title":"Curr Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.onc.1207042","article-title":"Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy","volume":"23","author":"Bossi","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/hed.20529","article-title":"Restoration of wild-type p53 function in human cancer: relevance for tumor therapy","volume":"29","author":"Bossi","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.cdd.4401243","article-title":"p53: 25years of research and more questions to answer","volume":"10","author":"Bourdon","year":"2003","journal-title":"Cell Death Diff"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11010-013-1688-5","article-title":"p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells","volume":"381","author":"Braicu","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/379339a0","article-title":"Normal host prion protein necessary for scrapie-induced neurotoxicity","volume":"379","author":"Brandner","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0205","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1471-4159.2006.04291.x","article-title":"p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease","volume":"100","author":"Bretaud","year":"2007","journal-title":"J Neurochem"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2013.11.009_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/0264-6021:3520511","article-title":"PrPSc-like prion protein peptide inhibits the function of cellular prion protein","volume":"352","author":"Brown","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2010.11.004","article-title":"Reactivation of p53: from peptides to small molecules","volume":"32","author":"Brown","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0215","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0225","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1042\/BST0380967","article-title":"From tau phosphorylation to tau aggregation: what about neuronal death?","volume":"38","author":"Buee","year":"2010","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0230","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","article-title":"Mice devoid of PrP are resistant to scrapie","volume":"73","author":"B\u00fceler","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0235","doi-asserted-by":"crossref","first-page":"e29789","DOI":"10.1371\/journal.pone.0029789","article-title":"Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease","volume":"7","author":"Buizza","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/35094077","article-title":"Rescuing the function of mutant p53","volume":"1","author":"Bullock","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0245","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0361-9230(99)00136-7","article-title":"alpha-Synuclein and Parkinson's disease","volume":"50","author":"Burke","year":"1999","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0250","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1474-4422(05)70157-5","article-title":"Possible role for p53 in Huntington's disease","volume":"4","author":"Burton","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0255","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1523\/JNEUROSCI.1701-08.2008","article-title":"Endocytosis of prion protein is required for ERK1\/2 signaling induced by stress-inducible protein 1","volume":"28","author":"Caetano","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0265","series-title":"Study on Ab34 Biology and Detection in Transgenic Mice Brain and Human CSF","author":"Caillava","year":"2013"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0260","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ana.410230408","article-title":"Successful chemotherapy for recurrent malignant oligodendroglioma","volume":"23","author":"Cairncross","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0270","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1471-4159.2006.03648.x","article-title":"Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss","volume":"96","author":"Campbell","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0275","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0280","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s10495-010-0480-1","article-title":"The relationship between the 20S proteasomes and prion-mediated neurodegenerations: potential therapeutic opportunities","volume":"15","author":"Cecarini","year":"2010","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0285","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1582-4934.2008.00163.x","article-title":"Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease","volume":"12","author":"Cenini","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0290","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ceb.2013.07.005","article-title":"Stressing the cell cycle in senescence and aging","volume":"25","author":"Chandler","year":"2013","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cell.2005.09.028","article-title":"a-synuclein cooperates with CSPa in preventing neurodegeneration","volume":"123","author":"Chandra","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0300","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0305","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0310","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1046\/j.1471-4159.1995.65041431.x","article-title":"Processing of the b-amyloid precursor protein and its regulation in Alzheimer's disease","volume":"65","author":"Checler","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0325","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm.3332","article-title":"Alzheimer's and prion diseases: PDK1 at the crossroads","volume":"19","author":"Checler","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0315","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(00)00039-9","article-title":"Role of the proteasome in Alzheimer's disease","volume":"1502","author":"Checler","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0320","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000283483","article-title":"p53 is regulated by and regulates members of the gamma-secretase complex","volume":"7","author":"Checler","year":"2010","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg1990","article-title":"The evolution of gene regulation by transcription factors and microRNAs","volume":"8","author":"Chen","year":"2007","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0335","doi-asserted-by":"crossref","first-page":"19173","DOI":"10.1074\/jbc.270.32.19173","article-title":"Truncated forms of the human prion protein in normal brain and in prion disease","volume":"270","author":"Chen","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0340","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/emboj\/cdf324","article-title":"Cellular prion protein transduces neuroprotective signals","volume":"21","author":"Chiarini","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0345","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5483\/BMBRep.2006.39.3.253","article-title":"Transduced Tat-a-synuclein protects against oxidative stress in vitro and in vivo","volume":"39","author":"Choi","year":"2006","journal-title":"Biochem Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0350","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3727\/096368910X557173","article-title":"Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-alpha","volume":"20","author":"Chou","year":"2011","journal-title":"Cell Transplant"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0355","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-2001-3208","article-title":"Apoptotic neurons in Alzheimer's disease frequently show intracellular Abeta42 labeling","volume":"3","author":"Chui","year":"2001","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0360","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2990.2007.00829.x","article-title":"Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis","volume":"33","author":"Colin","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0365","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jnnp.2004.048660","article-title":"Molecular neurology of prion disease","volume":"76","author":"Collinge","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0375","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W","article-title":"Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas","volume":"79","author":"Coons","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0380","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1158\/0008-5472.CAN-07-1585","article-title":"MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth","volume":"67","author":"Corney","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0385","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","article-title":"What genetics tells us about the causes and mechanisms of Parkinson's disease","volume":"91","author":"Corti","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0390","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1073\/pnas.78.1.41","article-title":"Detection of a common feature in several human tumor cell lines\u2014a 53,000-dalton protein","volume":"78","author":"Crawford","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0395","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/156720506778249461","article-title":"Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders","volume":"3","author":"Culmsee","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0400","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2174\/156652407782564426","article-title":"DJ-1: a newcomer in Parkinson's disease pathology","volume":"7","author":"da Costa","year":"2007","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0035","doi-asserted-by":"crossref","first-page":"24065","DOI":"10.1074\/jbc.M002413200","article-title":"Wild-type but not Parkinson's disease-related Ala53Thr-a-synuclein protect neuronal cells from apoptotic stimuli","volume":"275","author":"da Costa","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4161\/cc.9.1.10420","article-title":"A novel parkin-mediated transcriptional function links p53 to familial Parkinson's disease","volume":"9","author":"da Costa","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0040","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cellsig.2010.10.020","article-title":"Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?","volume":"23","author":"da Costa","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0045","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1074\/jbc.M513903200","article-title":"6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation","volume":"281","author":"da Costa","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0050","doi-asserted-by":"crossref","first-page":"37330","DOI":"10.1074\/jbc.M306083200","article-title":"\u03b2-Synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase-3 activation","volume":"278","author":"da Costa","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0410","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ncb1981","article-title":"Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease","volume":"11","author":"da Costa","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0415","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/excr.1997.3766","article-title":"Geldanamycin prevents nuclear translocation of mutant p53","volume":"237","author":"Dasgupta","year":"1997","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0420","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1471-4159.2009.06485.x","article-title":"Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides","volume":"112","author":"Davenport","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0425","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-510X(97)00131-7","article-title":"Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease","volume":"152","author":"de la Monte","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0430","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","article-title":"Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein","volume":"391","author":"De Strooper","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0435","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1074\/jbc.M109.083469","article-title":"SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53","volume":"285","author":"Demma","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0440","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.2174\/1381612811319180009","article-title":"Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy","volume":"19","author":"Devine","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2009.10.087","article-title":"The amyloid-beta25-35 injection into the CA1 region of the neonatal rat hippocampus impairs the long-term memory because of an increase of nitric oxide","volume":"468","author":"Diaz","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0450","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12031-013-9962-2","article-title":"Cellular prion protein participates in the regulation of inflammatory response and apoptosis in BV2 microglia during infection with Mycobacterium bovis","volume":"51","author":"Ding","year":"2013","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0455","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/356215a0","article-title":"Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours","volume":"356","author":"Donehower","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0460","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/NEN.0b013e3182084a8c","article-title":"Optical imaging detects apoptosis in the brain and peripheral organs of prion-infected mice","volume":"70","author":"Drew","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0465","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.10350","article-title":"p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism","volume":"52","author":"Duan","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0470","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1046\/j.1471-4159.2001.00513.x","article-title":"The caspase-derived C-terminal fragment of betaAPP induces caspase-independent toxicity and triggers selective increase of Abeta42 in mammalian cells","volume":"78","author":"Dumanchin-Njock","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0475","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1074\/jbc.M611572200","article-title":"p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the {gamma}-secretase complex but is independent of its activity","volume":"282","author":"Dunys","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0480","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1242\/jcs.051169","article-title":"p53-dependent control of transactivation of the Pen2 promoter by presenilins","volume":"122","author":"Dunys","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0485","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1242\/jcs.127340","article-title":"ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1","volume":"126","author":"Duplan","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0490","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jmcb\/mjt003","article-title":"Parkin differently regulates presenilin-1 and presenilin-2 function by direct control of their promoter transcription","volume":"5","author":"Duplan","year":"2013","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0495","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-4274(02)00428-9","article-title":"Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease","volume":"139","author":"Eberhardt","year":"2003","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0500","doi-asserted-by":"crossref","first-page":"37311","DOI":"10.1074\/jbc.M406228200","article-title":"Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1","volume":"279","author":"Edbauer","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0505","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ng0492-45","article-title":"Definition of a consensus binding site for p53","volume":"1","author":"el-Deiry","year":"1992","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0510","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/316158a0","article-title":"Overproduction of p53 antigen makes established cells highly tumorigenic","volume":"316","author":"Eliyahu","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0515","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/312646a0","article-title":"Participation of p53 cellular tumour antigen in transformation of normal embryonic cells","volume":"312","author":"Eliyahu","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0520","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/8820","article-title":"Synphilin-1 associates with a-synuclein and promotes the formation of cytosolic inclusions","volume":"22","author":"Engelender","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0525","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/j.1460-2075.1991.tb07676.x","article-title":"Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line","volume":"10","author":"Fakharzadeh","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0530","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.febslet.2008.03.003","article-title":"Sumoylation is critical for DJ-1 to repress p53 transcriptional activity","volume":"582","author":"Fan","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0535","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1074\/jbc.M707176200","article-title":"DJ-1 decreases Bax expression through repressing p53 transcriptional activity","volume":"283","author":"Fan","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.onc.1209021","article-title":"p53 tumor suppressor protein regulates the levels of huntingtin gene expression","volume":"25","author":"Feng","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0545","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1074\/jbc.273.15.8545","article-title":"Lactacystin, proteasome function, and cell fate","volume":"273","author":"Fenteany","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0550","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.7732382","article-title":"Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin","volume":"268","author":"Fenteany","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0555","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","article-title":"The p53 proto-oncogene can act as a suppressor of transformation","volume":"57","author":"Finlay","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-2012-112186","article-title":"Evidence that the amyloid-beta protein precursor intracellular domain, AICD, derives from beta-secretase-generated C-terminal fragment","volume":"30","author":"Flammang","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0565","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1074\/jbc.M211485200","article-title":"Identification of a b-secretase activity, which truncates amyloid b-peptides after its presenilin-dependent generation","volume":"278","author":"Fluhrer","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0570","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.neurobiolaging.2008.09.018","article-title":"A role for p53 in the beta-amyloid-mediated regulation of the lysosomal system","volume":"31","author":"Fogarty","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0575","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12640-011-9277-4","article-title":"Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death","volume":"22","author":"Folch","year":"2012","journal-title":"Neurotox Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0580","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1073\/pnas.0409713102","article-title":"Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein","volume":"102","author":"Fornai","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0585","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","article-title":"aph-1 and pen2 are required for notch pathway signaling, g-secretase cleavage of bAPP and presenilin protein accumulation","volume":"3","author":"Francis","year":"2002","journal-title":"Dev Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0590","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1073\/pnas.241629998","article-title":"A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants","volume":"99","author":"Friedler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0595","doi-asserted-by":"crossref","first-page":"24108","DOI":"10.1074\/jbc.M302458200","article-title":"Kinetic instability of p53 core domain mutants. Implications for rescue by small molecules","volume":"278","author":"Friedler","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0600","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/86.19.1458","article-title":"Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model","volume":"86","author":"Fujiwara","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0605","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1750-3639.1998.tb00187.x","article-title":"p53 and brain tumors: from gene mutations to gene therapy","volume":"8","author":"Fulci","year":"1998","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0610","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1021\/bi049399k","article-title":"Truncated carboxyl-terminal fragments of b-amyloid precursor protein are processed to amyloid b-proteins 40 and 42","volume":"43","author":"Funamoto","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0615","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1128\/MCB.12.6.2866","article-title":"A transcriptionally active DNA-binding site for human p53 protein complexes","volume":"12","author":"Funk","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0620","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev"},{"issue":"Spec No. 2","key":"10.1016\/j.pharmthera.2013.11.009_bb0625","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/hmg\/ddi308","article-title":"Molecular pathogenesis of Parkinson's disease","volume":"14","author":"Gandhi","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0630","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1034\/j.1399-0004.1998.5440401.x","article-title":"Genetics of Parkinson's disease","volume":"54","author":"Gasser","year":"1998","journal-title":"Clin Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0635","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/cdd.2009.116","article-title":"Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6","volume":"17","author":"Giaime","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0640","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1074\/jbc.M508619200","article-title":"Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway","volume":"281","author":"Giaime","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0645","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0650","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1471-4159.2009.06024.x","article-title":"The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3\/6 and MKK4\/7, in vitro","volume":"109","author":"Gloeckner","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0655","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0660","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bbamcr.2011.01.006","article-title":"Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone","volume":"1813","author":"Goncalves","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0665","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1242\/jcs.048090","article-title":"Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway","volume":"122","author":"Goodger","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0670","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1468-1331.2006.01336.x","article-title":"Parkinson's disease: the genetics of a heterogeneous disorder","volume":"13","author":"Gosal","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0675","doi-asserted-by":"crossref","first-page":"35235","DOI":"10.1074\/jbc.C100357200","article-title":"Distinct intramembrane cleavages of the b-amyloid precursor protein family resembling g-secretase-like cleavage of Notch","volume":"276","author":"Gu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0680","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2005.03.153","article-title":"Prospective therapeutic applications of p53 inhibitors","volume":"331","author":"Gudkov","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0685","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000333804","article-title":"alpha-Secretase-derived cleavage of cellular prion yields biologically active catabolites with distinct functions","volume":"10","author":"Guillot-Sestier","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0690","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/156652412799218912","article-title":"Cellular prion and its catabolites in the brain: production and function","volume":"12","author":"Guillot-Sestier","year":"2012","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0695","doi-asserted-by":"crossref","first-page":"35973","DOI":"10.1074\/jbc.M109.051086","article-title":"The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo","volume":"284","author":"Guillot-Sestier","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0700","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1046\/j.1471-4159.1999.0721019.x","article-title":"Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid b-peptide toxicity: central roles of superoxide production and caspase activation","volume":"72","author":"Guo","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0705","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/089198870201500407","article-title":"Familial Lewy body diseases","volume":"15","author":"Gwinn-Hardy","year":"2002","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0710","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/S0959-8049(96)00259-6","article-title":"Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas","volume":"32A","author":"Hagel","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0715","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: positive and negative feedback loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0720","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00401-011-0806-2","article-title":"Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms","volume":"121","author":"Hartlage-Rubsamen","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0725","first-page":"143","article-title":"Parkinson's disease. The apoptosis hypothesis revisited","volume":"86","author":"Hartmann","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0730","doi-asserted-by":"crossref","first-page":"23622","DOI":"10.1074\/jbc.M313784200","article-title":"b-synuclein regulates Akt activity in neuronal cells: a possible mechanism for neuroprotection in Parkinson's disease","volume":"279","author":"Hashimoto","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0735","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0740","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0745","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0750","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccr.2007.10.028","article-title":"p53 enters the microRNA world","volume":"12","author":"Hermeking","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0755","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0760","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-12-462002-5.50009-1","article-title":"The molecular genetics of Down syndrome","volume":"2","author":"Holtzman","year":"1992","journal-title":"Mol Genet Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0765","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011585","article-title":"Alzheimer disease in 2020","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0770","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neulet.2007.03.026","article-title":"p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells","volume":"418","author":"Hooper","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0775","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00401-012-1013-5","article-title":"The genetics and neuropathology of Parkinson's disease","volume":"124","author":"Houlden","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0780","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s10495-010-0466-z","article-title":"Ubiquitin\/proteasome pathway impairment in neurodegeneration: therapeutic implications","volume":"15","author":"Huang","year":"2010","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0785","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/mcne.1999.0811","article-title":"Identification of a novel aspartic protease (Asp2) as b-secretase","volume":"14","author":"Hussain","year":"1999","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0790","first-page":"689","article-title":"Prion peptide-mediated cellular prion protein overexpression and neuronal cell death can be blocked by aspirin treatment","volume":"27","author":"Jeong","year":"2011","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0795","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1471-4159.2001.00425.x","article-title":"Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases","volume":"78","author":"Junn","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0800","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1073\/pnas.95.14.8292","article-title":"Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2","volume":"95","author":"Kamijo","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0820","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.2353\/ajpath.2010.100680","article-title":"Molecular classification of low-grade diffuse gliomas","volume":"177","author":"Kim","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0805","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1096\/fj.14.11.1508","article-title":"Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity","volume":"14","author":"Kim","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0810","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1097\/00001756-199812010-00020","article-title":"C-terminal fragment of amyloid precursor protein inhibits calcium uptake into rat brain microsomes by Mg2+-Ca2+ ATPase","volume":"9","author":"Kim","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0815","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1046\/j.1471-4159.1996.67031172.x","article-title":"Neurotoxicity of a carboxyl-terminal fragment of the Alzheimer's amyloid precursor protein","volume":"67","author":"Kim","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0825","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1073\/pnas.1037392100","article-title":"g-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1 and pen-2","volume":"100","author":"Kimberly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0830","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cncr.11079","article-title":"Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas","volume":"97","author":"Kirla","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0835","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0840","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/bbrc.1997.6301","article-title":"Changes of p53 in the brains of patients with Alzheimer's disease","volume":"232","author":"Kitamura","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0845","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/01.wnl.0000271880.27321.a7","article-title":"Parkinson disease, 10years after its genetic revolution: multiple clues to a complex disorder","volume":"69","author":"Klein","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0850","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.devcel.2006.09.009","article-title":"The diverse functions of microRNAs in animal development and disease","volume":"11","author":"Kloosterman","year":"2006","journal-title":"Dev Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0855","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-2004-6606","article-title":"Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease","volume":"6","author":"Kobayashi","year":"2004","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0860","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effect of cancer therapy","volume":"285","author":"Komarov","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0865","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1126\/science.285.5434.1733","article-title":"A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy","volume":"285","author":"Komarov","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0870","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/156720512799361673","article-title":"AICD nuclear signaling and its possible contribution to Alzheimer's disease","volume":"9","author":"Konietzko","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0875","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2010.01.089","article-title":"Distribution of apoptosis-related proteins in sporadic Creutzfeldt\u2013Jakob disease","volume":"1323","author":"Kovacs","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0880","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0885","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/WCO.0b013e3283547627","article-title":"Genetics of Parkinson disease and other movement disorders","volume":"25","author":"Kumar","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0890","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02815217","article-title":"Neurodegeneration in Alzheimer disease. Is apoptosis involved?","volume":"28","author":"Kusiak","year":"1996","journal-title":"Mol Chem Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0900","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/278261a0","article-title":"T antigen is bound to a host protein in SV40-transformed cells","volume":"278","author":"Lane","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0895","doi-asserted-by":"crossref","first-page":"a000893","DOI":"10.1101\/cshperspect.a000893","article-title":"p53 research: the past thirty years and the next thirty years","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0905","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2010-1347","article-title":"Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease","volume":"20","author":"Lanni","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0910","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00294257","article-title":"Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ","volume":"89","author":"Lassmann","year":"1995","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0915","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/cdd.2009.77","article-title":"The multiple levels of regulation by p53 ubiquitination","volume":"17","author":"Lee","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0920","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1074\/jbc.M509509200","article-title":"Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death","volume":"281","author":"Lee","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0925","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0896-6273(00)81106-X","article-title":"Neurodegenerative tauopathies: human disease and transgenic mouse models","volume":"24","author":"Lee","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0930","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2006.03748.x","article-title":"The \u03b5-secretase-derived N-terminal product of the \u03b2-amyloid precursor protein behaves as a membrane-bound protein and undergoes \u03b1-, \u03b2-, and \u03b3-secretases cleavages","volume":"97","author":"Lefranc-Jullien","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0935","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0278-5846(03)00019-8","article-title":"Apoptosis and Parkinson's disease","volume":"27","author":"Lev","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0940","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-010-0204-y","article-title":"P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature","volume":"100","author":"Levidou","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0945","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0950","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12031-010-9443-9","article-title":"Cytosolic PrP induces apoptosis of cell by disrupting microtubule assembly","volume":"43","author":"Li","year":"2011","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0955","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1471-2164-10-201","article-title":"Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy","volume":"10","author":"Liang","year":"2009","journal-title":"BMC Genomics"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0960","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1073\/pnas.97.4.1456","article-title":"Human aspartyl protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein","volume":"97","author":"Lin","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0965","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1152\/physrev.00007.2007","article-title":"Physiology of the prion protein","volume":"88","author":"Linden","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0970","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0092-8674(79)90293-9","article-title":"Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells","volume":"17","author":"Linzer","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0975","doi-asserted-by":"crossref","first-page":"e57120","DOI":"10.1371\/journal.pone.0057120","article-title":"An intracellular threonine of amyloid-beta precursor protein mediates synaptic plasticity deficits and memory loss","volume":"8","author":"Lombino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0980","doi-asserted-by":"crossref","first-page":"11330","DOI":"10.1523\/JNEUROSCI.2313-05.2005","article-title":"Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways","volume":"25","author":"Lopes","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0985","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.1982.tb26840.x","article-title":"Down's syndrome, aging, and Alzheimer's disease: a clinical review","volume":"396","author":"Lott","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0990","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1000","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1073\/pnas.181340798","article-title":"Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors","volume":"98","author":"Lu","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb0995","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/74656","article-title":"A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor","volume":"6","author":"Lu","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2007.08.085","article-title":"Differential expression and protein distribution of Bax in natural scrapie","volume":"1180","author":"Lyahyai","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1010","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1074\/jbc.C111.298596","article-title":"Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease","volume":"287","author":"Ma","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1015","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/00005072-199710000-00003","article-title":"Molecular genetic evidence for subtypes of oligoastrocytomas","volume":"56","author":"Maintz","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/45095","article-title":"The tangled tale of tau","volume":"402","author":"Mandelkow","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2559.1988.tb02018.x","article-title":"Alzheimer's disease and Down's syndrome","volume":"13","author":"Mann","year":"1988","journal-title":"Histopathology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The role of alpha-synuclein in Parkinson's disease: insights from animal models","volume":"4","author":"Maries","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1523\/JNEUROSCI.4308-05.2006","article-title":"Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death","volume":"26","author":"Martin","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1471-4159.2001.00472.x","article-title":"Effect of the Alzheimer amyloid fragment Abeta(25\u201335) on Akt\/PKB kinase and survival of PC12 cells","volume":"78","author":"Martin","year":"2001","journal-title":"J Neurochem"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2013.11.009_bb1045","first-page":"II6","article-title":"Cell death in Parkinson's disease","volume":"249","author":"Maruyama","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00005072-199811000-00007","article-title":"Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease","volume":"57","author":"Masliah","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2010.06.005","article-title":"Drug discovery and mutant p53","volume":"20","author":"Maslon","year":"2010","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1060","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer's Disease and Down Syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.jnen.0000229238.05748.12","article-title":"Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels","volume":"65","author":"Matsui","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1070","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1091\/mbc.E11-04-0348","article-title":"Recruitment of cellular prion protein to mitochondrial raft-like microdomains contributes to apoptosis execution","volume":"22","author":"Mattei","year":"2011","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1075","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1947601911409736","article-title":"p53 in the CNS: perspectives on development, stem cells, and cancer","volume":"2","author":"Mendrysa","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1080","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","article-title":"The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor","volume":"149","author":"Meunier","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-1326-4-25","article-title":"Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation","volume":"4","author":"Milosevic","year":"2009","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1090","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3171\/jns.1996.85.6.1091","article-title":"Observer reliability in histological grading of astrocytoma stereotactic biopsies","volume":"85","author":"Mittler","year":"1996","journal-title":"J Neurosurg"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00019052-200108000-00008","article-title":"Parkin and Parkinson's disease","volume":"14","author":"Mizuno","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0022-510X(95)00336-Z","article-title":"Histochemical detection of apoptosis in Parkinson's disease","volume":"137","author":"Mochizuki","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neulet.2006.12.003","article-title":"p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain","volume":"414","author":"Mogi","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1110","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1073\/pnas.92.10.4407","article-title":"Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors","volume":"92","author":"Moll","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1115","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1073\/pnas.89.15.7262","article-title":"Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion","volume":"89","author":"Moll","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1120","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0006-8993(01)03074-8","article-title":"Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells","volume":"921","author":"Mookherjee","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1130","first-page":"5055","article-title":"Current status of gene therapy for lung cancer and head and neck cancer","volume":"9","author":"Moon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/07853890510007269","article-title":"Genetics of Parkinson's disease","volume":"37","author":"Morris","year":"2005","journal-title":"Ann Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1140","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1074\/jbc.M412767200","article-title":"Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy","volume":"280","author":"Muller","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1145","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.0b013e31829c5ec1","article-title":"Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study","volume":"81","author":"Musicco","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s007020200061","article-title":"Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy","volume":"109","author":"Nagatsu","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1155","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10495-006-6316-3","article-title":"Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease","volume":"11","author":"Nair","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1160","doi-asserted-by":"crossref","first-page":"39550","DOI":"10.1074\/jbc.M603950200","article-title":"p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition","volume":"281","author":"Nair","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1349-7006.2004.tb03163.x","article-title":"Isolation of p53-target genes and their functional analysis","volume":"95","author":"Nakamura","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(02)01255-2","article-title":"Parc: a cytoplasmic anchor for p53","volume":"112","author":"Nikolaev","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1175","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1167\/iovs.08-1849","article-title":"Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease","volume":"49","author":"Ning","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1215\/S1522851798000179","article-title":"Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression","volume":"1","author":"Nozaki","year":"1999","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1185","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","article-title":"Genetic pathways to glioblastoma: a population-based study","volume":"64","author":"Ohgaki","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","article-title":"Epidemiology and etiology of gliomas","volume":"109","author":"Ohgaki","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jnen\/64.6.479","article-title":"Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas","volume":"64","author":"Ohgaki","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1200","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10014-011-0029-1","article-title":"Genetic profile of astrocytic and oligodendroglial gliomas","volume":"28","author":"Ohgaki","year":"2011","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1096\/fj.04-2637fje","article-title":"Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease","volume":"19","author":"Ohyagi","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001756-200001170-00033","article-title":"Selective increase in cellular A beta 42 is related to apoptosis but not necrosis","volume":"11","author":"Ohyagi","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1220","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1225","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1230","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1074\/jbc.M311017200","article-title":"Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function","volume":"279","author":"Olzmann","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1235","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/hmg\/ddt068","article-title":"The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering","volume":"22","author":"Ottolini","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1240","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1523\/JNEUROSCI.0875-12.2012","article-title":"Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease","volume":"32","author":"Oul\u00e8s","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2006.09.162","article-title":"The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis","volume":"351","author":"Ozaki","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1250","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Paisan-Ruiz","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1255","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1046\/j.1471-4159.2002.01234.x","article-title":"Overexpression of PrPc triggers caspase 3 activation: potentiation by proteasome inhibitors and blockade by anti-PrP antibodies","volume":"83","author":"Paitel","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1260","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1074\/jbc.M211580200","article-title":"Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation","volume":"278","author":"Paitel","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1265","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1074\/jbc.M310453200","article-title":"Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels","volume":"279","author":"Paitel","year":"2004","journal-title":"J Biol Chem"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2013.11.009_bb1270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1471-4159.2011.07475.x","article-title":"The physiology of the beta-amyloid precursor protein intracellular domain AICD","volume":"120","author":"Pardossi-Piquard","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1471-4159.2009.05952.x","article-title":"p53-dependent control of cell death by nicastrin: lack of requirement for presenilin-dependent gamma-secretase complex","volume":"109","author":"Pardossi-Piquard","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1280","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JAD-2000-23-408","article-title":"Generation of an apoptotic intracellular peptide by g-secretase cleavage of Alzheimer's amyloid b protein precursor","volume":"2","author":"Passer","year":"2000","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1290","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-2012-111259","article-title":"Alzheimer's disease-related loss of Pin1 function influences the intracellular localization and the processing of AbetaPP","volume":"30","author":"Pastorino","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1084\/jem.20041502","article-title":"Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope","volume":"201","author":"Perfettini","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1300","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/35074581","article-title":"New protease inhibitors prevent gamma-secretase-mediated production of Abeta40\/42 without affecting Notch cleavage","volume":"3","author":"Petit","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1305","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1310","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bmc.2012.11.045","article-title":"Further characterization of a putative serine protease contributing to the gamma-secretase cleavage of beta-amyloid precursor protein","volume":"21","author":"Peuchmaur","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1315","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.3302","article-title":"PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer's diseases","volume":"19","author":"Pietri","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1320","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the a-synuclein gene identified in families with Parkinson Disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0092-8674(00)81400-2","article-title":"The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53","volume":"92","author":"Pomerantz","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1330","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","article-title":"Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease","volume":"80","author":"Prestia","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1335","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1340","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1038\/onc.2008.124","article-title":"Proteomic identification of p53-dependent protein phosphorylation","volume":"27","author":"Rahman-Roblick","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1345","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Raver-Shapira","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1350","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/cdd.2012.55","article-title":"The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production","volume":"19","author":"Robert","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1355","doi-asserted-by":"crossref","first-page":"a001016","DOI":"10.1101\/cshperspect.a001016","article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","volume":"2","author":"Robles","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1360","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1212\/01.WNL.0000152889.94785.51","article-title":"Alzheimer disease and cancer","volume":"64","author":"Roe","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1365","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/376775a0","article-title":"Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene","volume":"376","author":"Rogaev","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1370","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nm0798-835","article-title":"Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression","volume":"4","author":"Roperch","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1375","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1745-7254.2008.00731.x","article-title":"Advances in the genetics of Parkinson's disease","volume":"29","author":"Rosner","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1380","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(94)90436-7","article-title":"No propagation of prions in mice devoid of PrP","volume":"77","author":"Sailer","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1385","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1533317507302447","article-title":"Apoptotic gene expression in Alzheimer's disease hippocampal tissue","volume":"22","author":"Sajan","year":"2007","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1390","doi-asserted-by":"crossref","first-page":"14626","DOI":"10.1074\/jbc.M610514200","article-title":"MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation","volume":"282","author":"Sasaki","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1395","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/embo-reports\/kve180","article-title":"Presenilin dependent g-secretase processing of b-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch","volume":"2","author":"Sastre","year":"2001","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1400","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.gt.3300530","article-title":"Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging","volume":"4","author":"Scardigli","year":"1997","journal-title":"Gene Ther"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1405","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1410","doi-asserted-by":"crossref","first-page":"8821","DOI":"10.1128\/JVI.71.11.8821-8831.1997","article-title":"A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis","volume":"71","author":"Schatzl","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(98)00003-5","article-title":"Ubiquitin, E6-AP, and their role in p53 inactivation","volume":"78","author":"Scheffner","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1420","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology","volume":"14","author":"Schilling","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1425","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3940(98)00945-8","article-title":"Apoptosis-associated proteins p53 and APO-1\/Fas (CD95) in brains of adult patients with Down syndrome","volume":"260","author":"Seidl","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1430","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer's disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1435","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/neuonc\/4.3.171","article-title":"Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein","volume":"4","author":"Sembritzki","year":"2002","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1440","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1471-4159.2009.05950.x","article-title":"Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide","volume":"109","author":"Sevalle","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1445","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1242\/jcs.1125880","article-title":"Amyloid-beta signas through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease","volume":"126","author":"Seward","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1450","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/hmg\/5.7.985","article-title":"Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant","volume":"5","author":"Sherrington","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1455","doi-asserted-by":"crossref","first-page":"21286","DOI":"10.1074\/jbc.M209859200","article-title":"Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity","volume":"278","author":"Shi","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1460","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/77060","article-title":"Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase","volume":"25","author":"Shimura","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1465","first-page":"641","article-title":"DJ-1 restores p53 transcription activity inhibited by Topors\/p53BP3","volume":"26","author":"Shinbo","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1470","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0092-8674(00)81572-X","article-title":"Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions","volume":"93","author":"Shmerling","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1475","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/brain\/awn323","article-title":"Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology","volume":"132","author":"Simunovic","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1480","doi-asserted-by":"crossref","first-page":"a60","DOI":"10.2741\/singh","article-title":"Prion peptide 106\u2013126 as a model for prion replication and neurotoxicity","volume":"7","author":"Singh","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1485","doi-asserted-by":"crossref","DOI":"10.1126\/science.1090278","article-title":"Alpha-synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/990114","article-title":"Purification and cloning of amyloid precursor protein b-secretase from human brain","volume":"402","author":"Sinha","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1495","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddq086","article-title":"Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model","volume":"19","author":"Smith","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1500","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4161\/pri.20479","article-title":"Trafficking of PrPc to mitochondrial raft-like microdomains during cell apoptosis","volume":"6","author":"Sorice","year":"2012","journal-title":"Prion"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1505","first-page":"428","article-title":"Tau protein pathology in neurodegenerative diseases","volume":"21","author":"Spillantini","year":"1998","journal-title":"TIN"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1510","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1097-2765(01)00323-9","article-title":"Regulation of PTEN transcription by p53","volume":"8","author":"Stambolic","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1515","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.20432","article-title":"Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis","volume":"101","author":"Stander","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1520","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1097\/00001756-199412000-00031","article-title":"Immunohistochemical evidence for apoptosis in Alzheimer's disease","volume":"5","author":"Su","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1525","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001756-199601310-00015","article-title":"Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimer's disease","volume":"7","author":"Su","year":"1996","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1530","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/pr.54.3.469","article-title":"Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease","volume":"54","author":"Suh","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1535","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-8-29","article-title":"S-nitrosylaton of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease","volume":"8","author":"Sunico","year":"2013","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1540","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1471-4159.2004.02989.x","article-title":"Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis","volume":"92","author":"Sunyach","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1545","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1074\/jbc.M609663200","article-title":"The C-terminal products of cellular prion protein processing, C1 and C2, exert distinct influence on p53-dependent staurosporine-induced caspase-3 activation","volume":"282","author":"Sunyach","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1550","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1937-6448(08)01406-8","article-title":"Molecular and cellular biology of synucleins","volume":"270","author":"Surguchov","year":"2008","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1555","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00018-007-7270-0","article-title":"Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease","volume":"65","author":"Takahashi","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1560","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature01506","article-title":"The role of presenilin cofactors in the g-secretase complex","volume":"422","author":"Takasugi","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1565","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0306-4522(96)00545-3","article-title":"In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining","volume":"77","author":"Tatton","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1570","doi-asserted-by":"crossref","first-page":"22590","DOI":"10.1074\/jbc.M109.032599","article-title":"Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein","volume":"284","author":"Taylor","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1575","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00005072-199801000-00009","article-title":"N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposit","volume":"57","author":"Tekirian","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1580","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1038\/cddis.2011.21","article-title":"Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction","volume":"2","author":"Thellung","year":"2011","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1585","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.biocel.2007.03.022","article-title":"MDM2 and MDM4: p53 regulators as targets in anticancer therapy","volume":"39","author":"Toledo","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1590","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/neur.1996.0031","article-title":"Dopaminergic neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity","volume":"5","author":"Trimmer","year":"1996","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1595","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneurol.2013.132","article-title":"Advances in the genetics of Parkinson disease","volume":"9","author":"Trinh","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1600","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archneur.55.2.151","article-title":"Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia","volume":"55","author":"Trojanowski","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1610","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.neurobiolaging.2005.06.013","article-title":"Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients","volume":"27","author":"Uberti","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000113704","article-title":"Conformationally altered p53: a putative peripheral marker for Alzheimer's disease","volume":"5","author":"Uberti","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1605","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1242\/jcs.115.15.3131","article-title":"Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients","volume":"115","author":"Uberti","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1620","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1101\/gad.1399806","article-title":"Control of translation and mRNA degradation by miRNAs and siRNAs","volume":"20","author":"Valencia-Sanchez","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1625","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary early-onset Parkinson's disease caused by mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1630","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"\u03b2-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1635","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0161-813X(02)00081-5","article-title":"Abeta[25\u201335] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-kappaB, p53 and c-Jun","volume":"23","author":"Velez-Pardo","year":"2002","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00381-007-0449-8","article-title":"Prognosis of cerebellar astrocytomas in children","volume":"24","author":"Villarejo","year":"2008","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1645","doi-asserted-by":"crossref","first-page":"35612","DOI":"10.1074\/jbc.M004628200","article-title":"Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons","volume":"275","author":"Vincent","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1650","doi-asserted-by":"crossref","first-page":"37743","DOI":"10.1074\/jbc.M105677200","article-title":"The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein","volume":"276","author":"Vincent","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1655","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1523\/JNEUROSCI.0789-09.2009","article-title":"p53-Dependent transcriptional control of cellular prion by presenilins","volume":"29","author":"Vincent","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1660","author":"Viotti","year":"2013","journal-title":"Glioma Tumor Grades Correlates With Parkin Depletion in Mutant p53-linked Tumors and Results From Loss of Function of p53 Transcriptional Activity"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1665","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0092-8674(92)90421-8","article-title":"p53 function and dysfunction","volume":"70","author":"Vogelstein","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1670","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.11.009_bb9000","first-page":"611","article-title":"p53 mutation and protein alteration in 50 gliomas","volume":"12","author":"Von Eckardstein","year":"1997","journal-title":"Retrospective study by DNA-sequencing techniques and immunohistochemistry. Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1675","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1680","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1531-8249(200004)47:4<521::AID-ANA18>3.0.CO;2-B","article-title":"Synphilin-1 is present in Lewy bodies in Parkinson's disease","volume":"47","author":"Wakabayashi","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1685","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-2007-11105","article-title":"The significance of Pin1 in the development of Alzheimer's disease","volume":"11","author":"Wang","year":"2007","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1074\/jbc.M410649200","article-title":"Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol","volume":"280","author":"Wang","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1695","first-page":"523","article-title":"Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies","volume":"3","author":"Watanabe","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1700","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/jnen\/60.12.1181","article-title":"Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas","volume":"60","author":"Watanabe","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1705","doi-asserted-by":"crossref","first-page":"32603","DOI":"10.1074\/jbc.M702767200","article-title":"MDM2 chaperones the p53 tumor suppressor","volume":"282","author":"Wawrzynow","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1710","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/bi015794o","article-title":"A novel e-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with the Notch processing","volume":"41","author":"Weidemann","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1715","doi-asserted-by":"crossref","first-page":"153","DOI":"10.55782\/ane-2002-1434","article-title":"Molecular biology of prions","volume":"62","author":"Weissmann","year":"2002","journal-title":"Acta Neurobiol Exp"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1720","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","article-title":"Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network","volume":"27","author":"Weller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1725","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-009-0557-5","article-title":"Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model","volume":"118","author":"Wirths","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1730","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1074\/jbc.M111.314765","article-title":"Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking","volume":"287","author":"Woo","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1735","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/neuonc\/4.4.278","article-title":"Epidemiology of primary brain tumors: current concepts and review of the literature","volume":"4","author":"Wrensch","year":"2002","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1740","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuint.2013.05.006","article-title":"p38(MAPK)\/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease","volume":"63","author":"Wu","year":"2013","journal-title":"Neurochem Int"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1745","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.neuro.2004.12.008","article-title":"Selective alterations of transcription factors in MPP+-induced neurotoxicity in PC12 cells","volume":"26","author":"Xu","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1750","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/syn.20089","article-title":"Selective alterations of gene expression in mice induced by MPTP","volume":"55","author":"Xu","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1755","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/990107","article-title":"Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity","volume":"402","author":"Yan","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1760","first-page":"379","article-title":"Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease","volume":"152","author":"Yang","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1765","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm0896-850","article-title":"New clues to Alzheimer's disease: unraveling the roles of amyloid and tau","volume":"2","author":"Yankner","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1770","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2011.02.040","article-title":"Resistance against apoptosis by the cellular prion protein is dependent on its glycosylation status in oral HSC-2 and colon LS 174T cancer cells","volume":"306","author":"Yap","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1775","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/CBI20110088","article-title":"Resistance against tumour necrosis factor alpha apoptosis by the cellular prion protein is cell-specific for oral, colon and kidney cancer cell lines","volume":"36","author":"Yap","year":"2012","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1780","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/35024009","article-title":"Nicastrin modulates presenilin-mediated notch\/glp1 signal transduction and bAPP processing","volume":"407","author":"Yu","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1785","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1093\/emboj\/cdf325","article-title":"Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection","volume":"21","author":"Zanata","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1790","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(03)01139-2","article-title":"Why did p53 gene therapy fail in ovarian cancer?","volume":"4","author":"Zeimet","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1795","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1073\/pnas.1113884108","article-title":"Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1800","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nature07443","article-title":"p53 and Pten control neural and glioma stem\/progenitor cell renewal and differentiation","volume":"455","author":"Zheng","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1810","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1073\/pnas.1118090109","article-title":"Highly neurotoxic monomeric alpha-helical prion protein","volume":"109","author":"Zhou","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1805","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S0317167100009975","article-title":"Proteasome inhibitor lactacystin induces cholinergic degeneration","volume":"37","author":"Zhou","year":"2010","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1815","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-7819-11-22","article-title":"Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells","volume":"11","author":"Zhu","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1820","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1021\/jm020044d","article-title":"Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives","volume":"45","author":"Zhu","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2013.11.009_bb1825","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:49:51Z","timestamp":1716202191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":365,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0163725813002271"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p53 in neurodegenerative diseases and brain cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}